Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca
Go back to Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca| (NASDAQ: CADL) | Delayed: 9.15 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.15 | 52 Week High | $ | |||
| Open | $9.15 | 52 Week Low | $ | |||
| Day High | $9.15 | P/E | N/A | |||
| Day Low | $9.15 | EPS | $ | |||
| Volume | 12,502 | |||||
